The identification of increased risk by low levels of antibodies of TF for CVD mortality and bladder cancer and TD for bladder and colon cancer in the Oslo II study, Norway, opens the “window” of case identification (8, 9). The gene discussed is TF; the disease is malignant colon neoplasm.